Clinical Trials

57 results for Kidney/Renal Cancer


A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma

  • Condition: Renal Cell Carcinoma
  • Intervention: Device: CyberKnife
  • Study ID: NCT01890590
View Trial

A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer

  • Condition: Papillary Renal Cell Carcinoma
  • Intervention: Drug: INC280
  • Study ID: NCT02019693
View Trial

Star-tor - Registry For The Evaluation Of The Safety, Tolerability And Efficacy Of Temsirolimus (Torisel®), Sunitinib (Sutent®), And Axitnib (Inlyta®) For The Treatment Of Subjects With Advanced Renal Cell Carcinoma (Mrcc), Mantle Cell Lymphoma (Mcl), And

  • Condition: Carcinoma, Renal Cell, Advanced, Lymphoma, Mantle-Cell, Gastrointestinal Stroma Tumors
  • Intervention: Drug: Temsirolimus, Drug: Temsirolimus, Drug: Sunitinib, Drug: Sunitinib, Drug: Axitinib
  • Study ID: NCT00700258
View Trial

Axitinib In Advanced / Metastatic Renal Cell Carcinoma - A Non-interventional Study Of Real World Treatment Outcomes In Patients Receiving 2nd Line Axitinib After 1st Line Sunitinib (Adonis)

  • Condition: Metastatic Renal Cell Carcinoma (mRCC)
  • Intervention: Other: observational
  • Study ID: NCT02184416
View Trial

A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients With Advanced Solid Tumors

  • Condition: Adult Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Cancer, Recurrent Colorectal Carcinoma, Recurrent Melanoma, Recurrent Ovarian Carcinoma, Recurrent Renal Cell Carcinoma, Stage IV Ovarian Cancer, Stage IVA Colorectal Cancer, Stage
  • Intervention: Other: Laboratory Biomarker Analysis, Biological: Pembrolizumab, Biological: Ziv-Aflibercept
  • Study ID: NCT02298959
View Trial

Concurrent Chemoradiation With or Without DC-CIK Immunotherapy in Treating Locally Advanced Esophageal Cancer

  • Condition: Esophageal Carcinoma
  • Intervention: Other: concurrent chemoradiotherapy plus DC-CIK immunotherapy, Other: Concurrent chemoradiation only
  • Study ID: NCT01691625
View Trial

Combined Haploidentical Reduced Intensity Bone Marrow and Kidney Transplantation for Patients With Chronic Kidney Disease and Advanced Hematological Disorders

  • Condition: Chronic Kidney Disease, Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Myelogenous Leukemia (CML), Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL), Hodgkin Disease, Multiple Myeloma, Myelodysplastic Synd
  • Intervention: Procedure: Haploidentical Bone Marrow/Kidney
  • Study ID: NCT01758042
View Trial

177Lu-PP-F11N for Receptor Targeted Therapy and Imaging (Theranostics) of Metastatic Medullary Thyroid Cancer - a Pilot and a Phase I Study.

  • Condition: Thyroid Cancer, Medullary
  • Intervention: Drug: 177Lu-PP-F11N
  • Study ID: NCT02088645
View Trial

An Open-label, Phase II, Registry Study of Lutetium-177 [DOTA0, Tyr3] Octreotate (Lu-DOTA-TATE) Treatment in Subjects With Somatostatin Receptor Positive Tumours

  • Condition: Carcinoma, Neuroendocrine
  • Intervention: Other: Lu-DOTA-TATE radiopharmaceutical
  • Study ID: NCT01876771
View Trial

Predictors of Response to Neoadjuvant Docetaxel-Carboplatin Chemotherapy for Patients With Stage II and III Triple Negative Breast Cancer

  • Condition: Breast Cancer, Breast Cancer Stage II-III
  • Intervention: Drug: Docetaxel- Carboplatin
  • Study ID: NCT01560663
View Trial

Impact of a Melatonin Supplementation on the Quality of Life in Elderly Metastatic Cancer Patients (> = 70 Years) - PHRC-K13-170

  • Condition: Cancer
  • Intervention: Drug: melatonin, Drug: placebo
  • Study ID: NCT02454855
View Trial

Hematopoietic Stem Cell Transplant for Sickle Cell Disease

  • Condition: Sickle Cell Disease, Sickle Cell Anemia, SCD
  • Intervention: Drug: Fludarabine, Procedure: Hematopoietic Stem Cell Transplant (HSCT)
  • Study ID: NCT02065596
View Trial

GASTRICHIP : D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma. A Randomized and Multicentric Phase III Study.

  • Condition: Gastric Adenocarcinoma
  • Intervention: Drug: HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) with oxaliplatin, Procedure: Curative gastrectomy
  • Study ID: NCT01882933
View Trial

A Randomized Double-blind Phase II Study Evaluating the Role of Maintenance Therapy With Cabozantinib in High Grade Undifferentiated Uterine Sarcoma (HGUS) After Stabilization or Response to Doxorubicin +/- Ifosfamide Following Surgery or in Metastatic Fi

  • Condition: Uterine Sarcoma
  • Intervention: Drug: Cabozantinib, Drug: Placebo
  • Study ID: NCT01979393
View Trial

A Randomized Phase II Study to Evaluate the Efficacy and Safety of Chemotherapy (CT) vs Androgen Deprivation Therapy (ADT) in Patients With Recurrent and/or Metastatic, Androgen Receptor (AR) Expressing, Salivary Gland Cancer (SGCs)

  • Condition: Salivary Gland Cancer
  • Intervention: Drug: bicalutamide + triptorelin, Drug: Cisplatin + Doxorubicin, Drug: Carboplatin + Paclitaxel
  • Study ID: NCT01969578
View Trial

Phase Ib Trial Of Pembrolizumab And Nintedanib

  • Condition: Patients With Any Advanced Solid Tumors.
  • Intervention: Drug: Nintedanib, Drug: Pembrolizumab
  • Study ID: NCT02856425
View Trial

A National, Prospective, Non-Interventional Study (NIS) of Nivolumab (BMS-936558) in Patients With Advanced Renal Cell Carcinoma After Prior Therapy

  • Condition: Renal Cell Carcinoma
  • Intervention: Other: Non Interventional
  • Study ID: NCT02940639
View Trial

Phase I/II Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA)

  • Condition: Renal Cell Carcinoma
  • Intervention: Drug: Sunitinib, Drug: Bevacizumab
  • Study ID: NCT02919371
View Trial

Kidney Cancer DNA Registry

  • Condition: Renal Cancer
  • Intervention: Other: salvia for germline DNA, Behavioral: the Kidney Cancer Questionnaire, Behavioral: Family History Questionnaire (when applicable)
  • Study ID: NCT02087852
View Trial

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

  • Condition: Urothelial Carcinoma, Renal Cell Carcinoma
  • Intervention: Drug: cabozantinib, Drug: atezolizumab, Drug: cabozantinib
  • Study ID: NCT03170960
View Trial

A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid or Cetuximab in Patients With Advanced Malignancy and Other Indications

  • Condition: Advanced Cancers
  • Intervention: Drug: Temsirolimus, Drug: Bevacizumab, Drug: Valproic Acid, Drug: Cetuximab
  • Study ID: NCT01552434
View Trial

caBozantinib in cOllectiNg ductS Renal Cell cArcInoma (BONSAI)

  • Condition: Metastatic Collecting Duct Renal Cell Carcinoma
  • Intervention: Drug: Cabometyx
  • Study ID: NCT03354884
View Trial

Cabosun II: Cabozantinib Versus Sunitinib for Metastatic Variant Histology Renal Cell Carcinoma

  • Condition: Malignant Neoplasms of Urinary Tract, Renal Cell Carcinoma
  • Intervention: Drug: Cabozantinib, Drug: Sunitinib
  • Study ID: NCT03541902
View Trial

Prospective Non Interventional Study of Cabozantinib Tablets in Adults With Advanced Renal Cell Carcinoma Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy

  • Condition: Renal Cell Carcinoma
  • Intervention: Other: Data collection
  • Study ID: NCT03419572
View Trial

A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (BMS-936558, Anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors

  • Condition: Advanced Cancer
  • Intervention: Drug: BMS-986205, Drug: Nivolumab
  • Study ID: NCT02658890
View Trial

A Phase 2 Open-Label Study of Nivolumab Combined With Cabozantinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma (CA209-9KU)

  • Condition: Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma
  • Intervention: Drug: cabozantinib, Drug: nivolumab
  • Study ID: NCT03635892
View Trial

Prospective Non-interventional Study of Cabozantinib in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment

  • Condition: Advanced or Metastatic Renal Cell Carcinoma
  • Study ID: NCT03647878
View Trial

A Phase 2 Trial of PT2977 in Combination With Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

  • Condition: RCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer, Renal Cancer, Renal Cell Carcinoma, Renal Cell Cancer Metastatic, Renal Cell Carcinoma Recurrent, Renal Cell Cancer, Recurrent, Kidney
  • Intervention: Drug: PT2977 in combination with cabozantinib tablets
  • Study ID: NCT03634540
View Trial

Preventive Effects of Low-dose Aspirin as Adjuvant Therapy After Radical Nephrectomy on Disease Recurrence/Metastasis and Survival in Patients With Locally Advanced Renal Cell Carcinoma: an Observational Prospective Cohort Study

  • Condition: Aspirin as Adjuvant Therapy in Patients With Surgically Treated High Risk Renal Cell Carcinoma
  • Intervention: Drug: Low dose of aspirin
  • Study ID: NCT03734614
View Trial

A Study of Anti-PD-1( Pembrolizumab) Combinations of D-CIK (Cytokine-induced Killer Cells Are Stimulated Using Mature Dendritic Cells) Immunotherapy and Axitinib in Advanced Ranal Carcinoma

  • Condition: Renal Cancer Metastatic
  • Intervention: Biological: Combinations treatment
  • Study ID: NCT03736330
View Trial

BIOREN (Predictive BIOmarkers in Metastatic RENal Cancer) - A Translational Study on Immunotherapy for Metastatic Renal Cancer

  • Condition: Renal Cancer Metastatic
  • Intervention: Biological: Immunological and tumour characterization
  • Study ID: NCT03628859
View Trial

Famitinib Malate Plus Anti-PD1 Therapy (SHR-1210) in Advanced Renal Cell Carcinoma, Urothelial Carcinoma, Advanced Cervical Cancer, Relapse Ovarian Cancer, Endometrial Cancer: Multi-institutional, Open-label, Phase 2 Trial

  • Condition: Renal Cell Carcinoma, Urothelial Carcinoma, Cervical Cancer, Ovarian Cancer Recurrent, Endometrial Cancer
  • Intervention: Biological: SHR-1210, Drug: Famitinib
  • Study ID: NCT03827837
View Trial

Development and Evaluation of High Risk Group Prediction Model in T1 Stage Renal Cell Cancer Using Molecular Biomarkers

  • Condition: Clear Renal Cell Cancer (< 7cm Size)
  • Intervention: Procedure: Partial or radical nephrectomy
  • Study ID: NCT03694912
View Trial

Phase II Study: Stereotactic Ablative Radiotherapy for Renal Tumors

  • Condition: Renal Tumor
  • Intervention: Radiation: Stereotactic Ablative Radiotherapy
  • Study ID: NCT03747133
View Trial

Phase II Trial of AZD6738 Alone and in Combination With Olaparib in Patients With Selected Solid Tumor Malignancies

  • Condition: Clear Cell Renal Cell Carcinoma, Locally Advance Pancreatic Ductal Adenocarcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Renal Cell Carcinoma, Metastatic Urothelial Carcinoma, Pancreatic Ductal Ad
  • Intervention: Drug: ATR Kinase Inhibitor AZD6738, Drug: Olaparib
  • Study ID: NCT03682289
View Trial

A Phase I Open Label, Safety And Preliminary Efficacy Study of MRx0518 In Combination With Pembrolizumab In Patients With Advanced Malignancies Who Have Progressed On PD-1 Inhibitors

  • Condition: Oncology, Solid Tumor, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma, Bladder Cancer
  • Intervention: Drug: MRx0518, Drug: Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
  • Study ID: NCT03637803
View Trial

A Prospective, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial Evaluating the Use of Perioperative Intravenous Lidocaine Infusion to Decrease Pain Scores and Opioid Consumption After Robotic-Assisted Prostatectomy and Robotic-Assisted Partia

  • Condition: Kidney Cancer, Prostate Cancer
  • Intervention: Drug: Lidocaine Hydrochloride 0.8% in Dextrose 5% Solution, Drug: 0.9% Sodium Chloride Injection
  • Study ID: NCT03824808
View Trial

Molecular Analysis for Therapy Choice (MATCH)

  • Condition: Advanced Malignant Neoplasm, Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Plasma Cell Myeloma, Refractory Malignant Neoplasm, Refractory Plasma Cell Myeloma
  • Intervention: Drug: Afatinib, Drug: Akt inhibitor AZD5363, Drug: Binimetinib, Drug: Crizotinib, Other: Cytology Specimen Collection Procedure, Drug: Dabrafenib, Drug: Dasatinib, Drug: Defactinib, Drug: FGFR Inhibitor AZD4547, Other: Laboratory Biomarker Analysis, Biological: Nivolumab, Drug: Osimertinib, Drug: Palbociclib, Biological: Pertuzumab, Drug: PI3K-beta Inhibitor GSK2636771, Drug: Sapanisertib, Drug: Sunitinib Malate, Drug: Taselisib, Drug: Trametinib, Biological: Trastuzumab Emtansine, Drug: Trk Inhibitor LOXO-101, Drug: Vismodegib, Drug: WEE1 Inhibitor AZD1775
  • Study ID: NCT02465060
View Trial

FASTERCC: Folic Acid Supplement Versus Placebo for Treating Mucositis Adverse Events in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapy. A Randomized, Double-blind Trial From the Danish Renal Cancer Group (DARENCA Study-4)

  • Condition: Mucositis
  • Intervention: Drug: Folic Acid, Drug: Placebo Oral Tablet
  • Study ID: NCT03581773
View Trial

A Phase III Study Testing the Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic Renal Cell Carcinoma Treated With Sunitinib

  • Condition: Renal Cell Carcinoma, Metastatic, Renal Cell Cancer, Recurrent
  • Intervention: Behavioral: Concomitant coaching
  • Study ID: NCT03013946
View Trial

An International Investigator-led Phase III Multi Arm Multi Stage Multi-centre Randomised Controlled Platform Trial of Adjuvant Therapy in Patients With Resected Primary Renal Cell Carcinoma (RCC) at High or Intermediate Risk of Relapse

  • Condition: Renal Cell Carcinoma
  • Intervention: Drug: Durvalumab, Drug: Tremelimumab
  • Study ID: NCT03288532
View Trial

A Phase 2 Study of Neoadjuvant Cabozantinib in Patients With Locally Advanced Non-Metastatic Clear Cell Renal Cell Carcinoma

  • Condition: Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8
  • Intervention: Drug: Cabozantinib
  • Study ID: NCT04022343
View Trial

Talazoparib and Avelumab in Genomically Defined Metastatic Renal Cell Carcinoma

  • Condition: Metastatic Renal Cell Carcinoma, Advanced Retinal Disease Carcinoma
  • Intervention: Drug: Talazoparib, Drug: Avelumab
  • Study ID: NCT04068831
View Trial

Cabozantinib in Adult Patients With Advanced Renal Cell Carcinoma Following Prior Systemic Check Point Inhibition Therapy: a Retrospective, Non-interventional Study

  • Condition: Advanced Renal Cell Carcinoma (All Subtypes), Metastatic Renal Cell Carcinoma (All Subtypes)
  • Intervention: Other: Documentation
  • Study ID: NCT04147143
View Trial

A Phase I Trial of Interleukin-2 (Aldesleukin) and Pembrolizumab Combination Therapy for Patients With Advanced Renal Cell Carcinoma

  • Condition: Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
  • Intervention: Biological: Aldesleukin, Biological: Pembrolizumab
  • Study ID: NCT03260504
View Trial

Monitoring of Treatment Related Toxicities From Oral Targeted Agents and Immunotherapy Among Patients With Advanced Renal Cell Carcinoma (RCC) Using Carevive Software, a Single-Arm Phase II Feasibility Study

  • Condition: Advanced Renal Cell Carcinoma
  • Intervention: Other: Carevive software
  • Study ID: NCT03229083
View Trial

Genetic Evaluation of Renal Cell Carcinoma; Predicting Biomarkers for Renal Cell Carcinoma

  • Condition: Kidney Cancer
  • Study ID: NCT03414827
View Trial

Phase II Clinical Study of PD-1 Monoclonal Antibody Combination With Autologous Cytokine-induced Killer Cell Immunotherapy in the Second-line Treatment of Metastatic Clear Cell Renal Cell Carcinoma

  • Condition: Metastic Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Second-line Treatment
  • Intervention: Biological: SHR-1210, Biological: CIK cells
  • Study ID: NCT03987698
View Trial

Phase I/II Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma

  • Condition: Renal Cell Carcinoma
  • Intervention: Drug: Nivolumab, Drug: Axitinib
  • Study ID: NCT03172754
View Trial

Phase II Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma. HCRN: GU16-260

  • Condition: Advanced Renal Cell Carcinoma
  • Intervention: Drug: Nivolumab 240 mg, Drug: Ipilimumab 1mg/kg, Drug: Nivolumab 3mg/kg, Drug: Nivolumab 360mg
  • Study ID: NCT03117309
View Trial